You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Details for Patent: 9,512,165

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,512,165 protect, and when does it expire?

Patent 9,512,165 protects ZURZUVAE and is included in one NDA.

This patent has sixty-seven patent family members in twenty-six countries.

Summary for Patent: 9,512,165

Scope and claims summary:

Title:	19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
Abstract:	Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein, R, R, R, R, R, R, R, R, and Rare as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
Inventor(s):	Martinez Botella Gabriel, Harrison Boyd L., Robichaud Albert Jean, Salituro Francesco G., Beresis Richard Thomas
Assignee:	SAGE THERAPEUTICS, INC.
Application Number:	US14785171
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 9,512,165

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biogen Inc	ZURZUVAE	zuranolone	CAPSULE;ORAL	217369-001	Oct 31, 2023		RX	Yes	No	9,512,165	⤷ Subscribe	Y	Y			⤷ Subscribe
Biogen Inc	ZURZUVAE	zuranolone	CAPSULE;ORAL	217369-002	Oct 31, 2023		RX	Yes	No	9,512,165	⤷ Subscribe	Y	Y			⤷ Subscribe
Biogen Inc	ZURZUVAE	zuranolone	CAPSULE;ORAL	217369-003	Oct 31, 2023		RX	Yes	Yes	9,512,165	⤷ Subscribe	Y	Y			⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,512,165

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014256229	⤷ Subscribe
Australia	2018278844	⤷ Subscribe
Australia	2020256400	⤷ Subscribe
Australia	2022205157	⤷ Subscribe
Brazil	112015026380	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.